Principal Financial Group Inc. increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,181,852 shares of the medical instruments supplier’s stock after purchasing an additional 58,416 shares during the quarter. Principal Financial Group Inc. owned 0.41% of Becton, Dickinson and worth $287,414,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the business. Solstein Capital LLC acquired a new position in shares of Becton, Dickinson and during the first quarter valued at $28,000. Meridian Wealth Partners LLC purchased a new position in Becton, Dickinson and in the 1st quarter worth about $28,000. Ameritas Investment Company LLC purchased a new position in Becton, Dickinson and in the 1st quarter worth about $39,000. Harbour Investments Inc. purchased a new position in Becton, Dickinson and in the 1st quarter worth about $42,000. Finally, Selective Wealth Management Inc. purchased a new position in Becton, Dickinson and in the 2nd quarter worth about $49,000. Institutional investors own 84.25% of the company’s stock.
Shares of NYSE BDX opened at $260.45 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.23 and a debt-to-equity ratio of 0.65. The business’s 50 day moving average is $250.72 and its two-hundred day moving average is $246.91. The company has a market cap of $74.80 billion, a P/E ratio of 40.89, a P/E/G ratio of 2.42 and a beta of 0.76. Becton, Dickinson and Company has a 12 month low of $219.50 and a 12 month high of $267.37.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 30th. Stockholders of record on Thursday, September 9th will be given a dividend of $0.83 per share. This represents a $3.32 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend is Wednesday, September 8th. Becton, Dickinson and’s dividend payout ratio is presently 32.55%.
A number of equities research analysts have commented on BDX shares. SVB Leerink decreased their price objective on Becton, Dickinson and from $260.00 to $250.00 and set a “market perform” rating for the company in a research report on Friday, August 6th. Barclays began coverage on Becton, Dickinson and in a report on Monday, May 24th. They set an “equal weight” rating and a $270.00 price target for the company. Zacks Investment Research upgraded Becton, Dickinson and from a “sell” rating to a “hold” rating and set a $262.00 price target for the company in a report on Tuesday, August 17th. Finally, JPMorgan Chase & Co. lowered Becton, Dickinson and from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $276.93 to $265.00 in a report on Friday, August 6th. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and presently has an average rating of “Hold” and a consensus price target of $272.33.
In related news, EVP James C. Lim sold 6,956 shares of the business’s stock in a transaction on Friday, September 3rd. The stock was sold at an average price of $257.44, for a total value of $1,790,752.64. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Thomas J. Spoerel sold 266 shares of the business’s stock in a transaction on Friday, August 6th. The shares were sold at an average price of $242.30, for a total value of $64,451.80. Following the completion of the sale, the vice president now directly owns 1,285 shares in the company, valued at approximately $311,355.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,093 shares of company stock worth $2,330,578. 0.76% of the stock is currently owned by company insiders.
About Becton, Dickinson and
Becton, Dickinson & Co is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.
See Also: What is the Quick Ratio?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.